PODD
$230.49
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Recent News
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.
How The Insulet (PODD) Narrative Is Shifting With Omnipod 5 And Rising Competition
Insulet’s modeled fair value per share has been tweaked from US$354.40 to US$354.12, a very small adjustment that still caught investors’ attention. That subtle move lines up with a research backdrop where many analysts are trimming price targets while keeping a generally constructive view on Omnipod 5, Type 2 diabetes adoption and the overall franchise, with others placing more emphasis on competition and sentiment risks. Read on to see how you can keep track of these shifting views and what...
Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness
If you are wondering whether Insulet's current share price lines up with its underlying value, you are not alone and this article will help you unpack that question step by step. Despite trading at US$219.84, the stock has seen a 7.2% decline over the last 7 days, a 12.4% decline over 30 days and is down 22.3% year to date and 13.9% over the past year, which can change how investors think about both upside potential and risk. These price moves are unfolding against a backdrop of ongoing...
Why Insulet (PODD) Is Down 7.2% After Omnipod 5 Recall Over Insulin Under-Delivery Risk
Earlier this week, Insulet announced a voluntary medical device correction and recall for specific Omnipod 5 pod lots in the US after detecting a manufacturing defect that can cause insulin under-delivery and has been linked to 18 serious adverse events, including hospitalizations and diabetic ketoacidosis. While the affected pods account for only about 1.5% of annual Omnipod 5 production and replacements are being provided at no cost, the episode spotlights quality control, regulatory, and...